WO2000068247A3 - Serine proteases - Google Patents

Serine proteases Download PDF

Info

Publication number
WO2000068247A3
WO2000068247A3 PCT/US2000/012207 US0012207W WO0068247A3 WO 2000068247 A3 WO2000068247 A3 WO 2000068247A3 US 0012207 W US0012207 W US 0012207W WO 0068247 A3 WO0068247 A3 WO 0068247A3
Authority
WO
WIPO (PCT)
Prior art keywords
serine protease
human serine
polypeptides
protease polypeptides
serine proteases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/012207
Other languages
French (fr)
Other versions
WO2000068247A2 (en
Inventor
Steven M Ruben
Yanggu Shi
Paul E Young
Jian Ni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to AU47003/00A priority Critical patent/AU4700300A/en
Priority to CA002373759A priority patent/CA2373759A1/en
Priority to EP00928826A priority patent/EP1179052A4/en
Priority to JP2000616221A priority patent/JP2002543777A/en
Publication of WO2000068247A2 publication Critical patent/WO2000068247A2/en
Publication of WO2000068247A3 publication Critical patent/WO2000068247A3/en
Priority to US09/946,633 priority patent/US20020119925A1/en
Anticipated expiration legal-status Critical
Priority to US10/125,459 priority patent/US20020192800A1/en
Priority to US10/319,519 priority patent/US20030175938A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)

Abstract

The present invention relates to novel human serine protease polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human serine protease polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human serine protease polypeptides.
PCT/US2000/012207 1999-05-07 2000-05-05 Serine proteases Ceased WO2000068247A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU47003/00A AU4700300A (en) 1999-05-07 2000-05-05 Serine proteases
CA002373759A CA2373759A1 (en) 1999-05-07 2000-05-05 Serine proteases
EP00928826A EP1179052A4 (en) 1999-05-07 2000-05-05 Serine proteases
JP2000616221A JP2002543777A (en) 1999-05-07 2000-05-05 Serine protease
US09/946,633 US20020119925A1 (en) 1999-05-07 2001-09-06 Serine proteases
US10/125,459 US20020192800A1 (en) 1999-05-07 2002-04-19 Serine proteases
US10/319,519 US20030175938A1 (en) 1999-05-07 2002-12-16 Serine protease polynucleotides, polypeptides, and antibodies

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US13323999P 1999-05-07 1999-05-07
US60/133,239 1999-05-07
US13516399P 1999-05-20 1999-05-20
US60/135,163 1999-05-20
US14700599P 1999-08-03 1999-08-03
US60/147,005 1999-08-03
US15293599P 1999-09-09 1999-09-09
US60/152,935 1999-09-09
US16297999P 1999-11-01 1999-11-01
US60/162,979 1999-11-01

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US59783900A Continuation-In-Part 1999-05-07 2000-06-20
US59784200A Continuation-In-Part 1999-05-07 2000-06-20
US09/946,633 Continuation-In-Part US20020119925A1 (en) 1999-05-07 2001-09-06 Serine proteases

Publications (2)

Publication Number Publication Date
WO2000068247A2 WO2000068247A2 (en) 2000-11-16
WO2000068247A3 true WO2000068247A3 (en) 2001-06-28

Family

ID=27537949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012207 Ceased WO2000068247A2 (en) 1999-05-07 2000-05-05 Serine proteases

Country Status (6)

Country Link
US (1) US20020192800A1 (en)
EP (1) EP1179052A4 (en)
JP (1) JP2002543777A (en)
AU (1) AU4700300A (en)
CA (1) CA2373759A1 (en)
WO (1) WO2000068247A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
US9359598B2 (en) 2004-04-12 2016-06-07 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784746B2 (en) 1999-11-18 2006-06-08 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
US20020031801A1 (en) * 2000-03-24 2002-03-14 Millennium Pharmaceuticals, Inc. 18806, a novel trypsin serine protease-like molecule and uses thereof
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
AU2000257489A1 (en) * 2000-06-20 2002-01-02 Human Genome Sciences, Inc. Polynucleotides encoding human serine proteases
AU2002310492A1 (en) 2001-06-20 2003-01-08 Immunex Corporation Dendritic cell transmembrane serine protease
EP1738767A1 (en) * 2001-10-31 2007-01-03 Alcon, Inc. Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma
CN1966725A (en) 2001-10-31 2007-05-23 爱尔康公司 Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
EP1660537A2 (en) 2003-08-14 2006-05-31 Dyax Corp. Endotheliase-2 ligands
KR101126423B1 (en) 2005-10-21 2012-07-11 카탈리스트 바이오사이언시즈, 인코포레이티드 Modified proteases that inhibit complement activation
ES2372709T3 (en) 2006-07-05 2012-01-25 Catalyst Biosciences, Inc. PROCEDURES FOR PROTEASES AND PROTEASES IDENTIFIED BY THE SAME PROCESSES.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033812A1 (en) * 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312205T3 (en) * 1998-03-10 2009-02-16 Genentech, Inc. NEW POLYPEPTIDE AND NUCLEIC ACIDS THAT CODE IT.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033812A1 (en) * 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK GENE SEQUENCE; 28 January 1999 (1999-01-28), NCI-CGAP: "National cancer institute, cancer genome anatomy project (CGAP), tumor gene index", XP002934403 *
REYNOLDS D.S. ET AL.: "Cloning of the cDNA and gene of mouse mast cell protease-6", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 6, 25 February 1991 (1991-02-25), pages 3847 - 3853, XP002934402 *
See also references of EP1179052A4 *
WONG G.W. ET AL.: "Identification of a new member of the tryptase family of mouse and human mast cell proteases which possesses a novel COOH-terminal hydrophobic extension", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 43, 22 October 1999 (1999-10-22), pages 30784 - 30793, XP002934404 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US9359598B2 (en) 2004-04-12 2016-06-07 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity

Also Published As

Publication number Publication date
EP1179052A2 (en) 2002-02-13
WO2000068247A2 (en) 2000-11-16
JP2002543777A (en) 2002-12-24
AU4700300A (en) 2000-11-21
CA2373759A1 (en) 2000-11-16
US20020192800A1 (en) 2002-12-19
EP1179052A4 (en) 2004-12-15

Similar Documents

Publication Publication Date Title
WO2001038486A3 (en) Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies
WO1998031800A3 (en) Human proteins
WO1998039446A3 (en) 70 human secreted proteins
WO1998039448A3 (en) 186 human secreted proteins
WO1998040483A3 (en) 28 human secreted proteins
EP1053245A4 (en) 45 HUMAN SECRETED PROTEINS
WO2001036432A3 (en) 18 human secreted proteins
WO2001032910A3 (en) 27 human secreted proteins
WO1998045712A3 (en) 20 human secreted proteins
EP1054958A4 (en) HUMAN SERINE PROTEASE AND SERPIN POLYPEPTIDES
WO2001034768A3 (en) 15 human secreted proteins
WO2001012776A3 (en) 18 human secreted proteins
WO2000017222A8 (en) 31 human secreted proteins
WO2000052136A3 (en) Human glycosylation enzymes
WO2000077026A8 (en) 49 human secreted proteins
WO2000073323A3 (en) Adam polynucleotides and polypeptides
WO2001062891A3 (en) 207 human secreted proteins
WO2000063230A3 (en) 49 human secreted proteins
WO2001008635A3 (en) Calcium channel transport polynucleotides, polypeptides, and antibodies
EP1042342A4 (en) 53 HUMAN SECRETED PROTEINS
WO2000058339A3 (en) 50 human secreted proteins
WO2001012775A8 (en) 25 human secreted proteins
WO2000061624A8 (en) 48 human secreted proteins
WO2000043495A3 (en) 33 human secreted proteins
WO2003031586A3 (en) Acrp30-like polynucleotides, polypeptides, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09946633

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2373759

Country of ref document: CA

Ref country code: CA

Ref document number: 2373759

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 616221

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000928826

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000928826

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000928826

Country of ref document: EP